Ketamine Therapy in Pennsylvania

Pennsylvania does not have state-specific regulations governing ketamine infusion therapy beyond the federal framework established by the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA). Ketamine is classified as a Schedule III controlled substance under the federal Controlled Substances Act, meaning that clinics operating in Pennsylvania must adhere to strict DEA registration requirements, proper storage protocols, and detailed record-keeping practices for all ketamine purchases and administrations. Physicians administering ketamine must hold a valid DEA registration and be licensed to practice medicine in Pennsylvania through the Pennsylvania State Board of Medicine or the Pennsylvania State Board of Osteopathic Medicine, depending on their credentials.

The administration of ketamine infusions in Pennsylvania is considered the practice of medicine and must be performed or directly supervised by a licensed physician. While nurse anesthetists (CRNAs) and other advanced practice providers may assist in clinical settings, the prescribing authority and overall medical oversight remain with the treating physician. Clinics offering esketamine (Spravato), the FDA-approved nasal spray form of ketamine for treatment-resistant depression, must comply with the FDA's Risk Evaluation and Mitigation Strategy (REMS) program, which requires that the medication be administered in a certified healthcare setting with a minimum two-hour observation period following each dose.

Pennsylvania ketamine clinics are also subject to broader state healthcare regulations, including those governing:

• Facility licensing and inspection requirements through the Pennsylvania Department of Health
• Informed consent documentation and patient privacy standards under HIPAA
• Controlled substance prescribing and dispensing guidelines set by the Pennsylvania Department of Drug and Alcohol Programs
• Mandatory use of the Pennsylvania Prescription Drug Monitoring Program (PDMP), known as PA PDMP, which tracks controlled substance prescriptions statewide

Patients considering ketamine therapy in Pennsylvania are encouraged to verify that their chosen clinic employs board-certified physicians, maintains transparent informed consent practices, and operates within a properly licensed medical facility. As the field of ketamine therapy continues to evolve, prospective patients and providers should monitor guidance from both state licensing boards and professional organizations such as the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) and the American Society of Anesthesiologists, which have published clinical practice guidelines to promote safe and ethical ketamine administration.